India's weight-loss market has become a hotbed of illegal activity, with powerful drugs like Mounjaro being sold without prescriptions and misused in ways that endanger public health. Our undercover investigation revealed how this injectable medication, originally intended for managing type-II diabetes and severe obesity under strict medical supervision, is increasingly being accessed through unregulated channels, ranging from local chemists to aesthetic clinics. These illicit practices have led to serious health risks for individuals seeking rapid weight loss, often without proper guidance or oversight. The situation came into sharp focus during an incident involving a man weighing over 209 kilograms who was unable to breathe due to his condition. A team at All India Institute of Medical Sciences (AIIMS) worked tirelessly to prepare him for bariatric surgery, ultimately helping him lose more than 50 kilograms. This case highlights the severity of obesity-related complications in India and underscores the urgent need for better healthcare infrastructure and regulation. However, it also reflects the growing desperation among patients who turn to unverified methods to achieve quick results. Mounjaro, which contains tirzepatide, a compound known to suppress appetite and reduce food intake, is approved for use in treating type-II diabetes and severe obesity. It requires a prescription from a licensed physician and must be administered under professional supervision. Despite these safeguards, our investigation uncovered widespread violations. In some cases, chemists and online vendors were selling the drug directly to consumers without any form of medical evaluation. Others were even offering it as part of cosmetic procedures in aesthetic salons, where unqualified practitioners were administering injections to clients seeking weight loss. In one instance, we observed a clinic in Delhi that claimed to offer “weight loss treatments” using Mounjaro. Staff members admitted they had no formal training in endocrinology or internal medicine yet routinely prescribed the drug based on customer requests. Such practices are not only unethical but also potentially life-threatening, as improper use of Mounjaro can lead to hypoglycemia, gastrointestinal issues, and other adverse effects. Patients who lack medical knowledge are particularly vulnerable to these dangers. The misuse of prescription medications for non-medical purposes is not unique to Mounjaro. Other weight-loss drugs, including phentermine and sibutramine, have also been found in circulation outside of regulated systems. These substances carry their own set of risks, including cardiovascular strain and dependency. While regulatory bodies such as the Central Drugs Standard Control Organization (CDSCO) have issued warnings against unauthorized distribution, enforcement remains inconsistent across states and regions. Healthcare professionals and patient advocacy groups have expressed concern over the rising trend of self-medication and unlicensed treatment centers. Dr. Ananya Sharma, a consultant endocrinologist in Mumbai, noted that while there is increasing awareness about obesity management, the demand for quick fixes continues to drive illegal markets. “Patients are often unaware of the potential consequences,” she said. “They’re looking for solutions, but they’re not getting them from qualified providers.” As the situation evolves, authorities are beginning to take notice. Some state governments have launched raids targeting unlicensed clinics and online pharmacies suspected of selling controlled medications. However, the scale of the problem suggests that more comprehensive measures are needed. This includes stricter monitoring of pharmaceutical sales, increased public education on safe weight-management practices, and greater investment in specialized obesity care services. The case of the 209-kilogram patient serves as both a cautionary tale and a call to action. It demonstrates the extreme lengths to which some individuals will go to address health concerns, often at great personal risk. As the weight-loss market continues to expand, so too does the need for stronger regulatory frameworks and accessible, affordable healthcare options. Until then, the dark side of India’s weight-loss industry will persist, fueled by profit and poor oversight.
★
Keep the news honest.
ObjectiveNews is reader-funded and ad-free — we show you the bias instead of hiding it. Support independent journalism for €4/month.
Become a Supporter
India
